MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Eleven Biotherapeutics Company Profile (NASDAQ:EBIO)

Consensus Ratings for Eleven Biotherapeutics (NASDAQ:EBIO) (?)
Ratings Breakdown: 1 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $6.00 (109.06% upside)

Analysts' Ratings History for Eleven Biotherapeutics (NASDAQ:EBIO)
Show:
DateFirmActionRatingPrice TargetActions
5/19/2015Leerink SwannLower Price TargetOutperform$23.00 -> $6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/3/2014Leerink SwannInitiated CoverageOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/3/2014Cowen and CompanyInitiated CoverageOutperform$35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/3/2014Citigroup Inc.Initiated CoverageBuy$35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/5/2013 forward)